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ABSTRACT
Background The Daily- PROactive and Clinical 
visit- PROactive Physical Activity (D- PPAC and C- PPAC) 
instruments in chronic obstructive pulmonary disease 
(COPD) combines questionnaire with activity monitor 
data to measure patients’ experience of physical activity. 
Their amount, difficulty and total scores range from 0 
(worst) to 100 (best) but require further psychometric 
evaluation.
Objective To test reliability, validity and responsiveness, 
and to define minimal important difference (MID), of the 
D- PPAC and C- PPAC instruments, in a large population 
of patients with stable COPD from diverse severities, 
settings and countries.
Methods We used data from seven randomised 
controlled trials to evaluate D- PPAC and C- PPAC 
internal consistency and construct validity by sex, age 
groups, COPD severity, country and language as well as 
responsiveness to interventions, ability to detect change 
and MID.
Results We included 1324 patients (mean (SD) age 
66 (8) years, forced expiratory volume in 1 s 55 (17)% 
predicted). Scores covered almost the full range from 
0 to 100, showed strong internal consistency after 
stratification and correlated as a priori hypothesised 
with dyspnoea, health- related quality of life and exercise 
capacity. Difficulty scores improved after pharmacological 
treatment and pulmonary rehabilitation, while amount 
scores improved after behavioural physical activity 
interventions. All scores were responsive to changes in 
self- reported physical activity experience (both worsening 
and improvement) and to the occurrence of COPD 
exacerbations during follow- up. The MID was estimated 
to 6 for amount and difficulty scores and 4 for total 
score.
Conclusions The D- PPAC and C- PPAC instruments are 
reliable and valid across diverse COPD populations and 
responsive to pharmacological and non- pharmacological 
interventions and changes in clinically relevant variables.
INTRODUCTION
Research has consistently shown that patients with 
chronic obstructive pulmonary disease (COPD) 
have lower physical activity levels than their healthy 
peers,1 that reduced physical activity predicts both 
exacerbations and mortality,2 and that many patients 
limit their physical activity to avoid symptoms.3 
Hence, understanding physical activity is a key to 
improve the prognosis in patients with COPD.
Physical activity in COPD has been mostly 
assessed in terms of frequency, intensity, time and 
type4 and quantified by means of activity moni-
tors or questionnaires.5 Other instruments have 
focused on quantifying the symptoms or quality of 
life in relation to physical activities.6 7 However, 
the patients’ experience of physical activity has 
been ignored despite patients with COPD typically 
describe an inability to complete the activities they 
enjoy because of their illness8 and report that treat-
ments that improve physical activity are of value to 
them.9 Until recently, no valid measurement tools 
Key messages
What is the key question?
 ► What is the validity and responsiveness of the 
Daily- PROactive and Clinical visit- PROactive 
Physical Activity (D- PPAC and C- PPAC) 
instruments in chronic obstructive pulmonary 
disease (COPD)?
What is the bottom line?
 ► The D- PPAC and C- PPAC instruments, 
combining questionnaire with activity monitor 
data, are reliable and valid across diverse COPD 
populations and responsive to drug and non- 
drug interventions.
Why read on?
 ► This study combined more than 1300 patients 
from seven randomised controlled trials, 
covering a range of countries, languages, COPD 
disease severities, ages, objective physical 
activity levels and clinical determinants, 
wider than what is usually seen in other 
questionnaire/patient- reported outcome 
development programmes.
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Chronic obstructive pulmonary disease
have been available to capture the experience of physical activity. 
In the framework of the European Union Innovative Medicines 
Initiative PROactive project, the PROactive Physical Activity in 
COPD instruments (Daily and Clinical visit versions, D- PPAC 
and C- PPAC) were developed following the recommendations 
of the US Food and Drug Administration (FDA) guidance.10 
In contrast with previous research, results of the development 
phase of PPAC instruments clearly showed that neither ques-
tionnaires nor activity monitors alone could discriminate well 
within the latent patient- centred construct ‘experience of phys-
ical activity’, while the combination of both achieved good 
discrimination at all ranges of the scale.11 In agreement with 
previous qualitative work,12 the development and initial valida-
tion of the PPAC instruments suggested that the concept ‘phys-
ical activity experience’ in patients with COPD is structured in 
two domains: ‘amount of physical activity’ and ‘difficulty with 
physical activity’. Thus, D- PPAC and C- PPAC combine question-
naire items and activity monitor variables to measure amount of 
physical activity, difficulty with physical activity and total phys-
ical activity experience.
A first validation study showed that both instruments are 
simple, reliable and valid measures of physical activity experi-
ence in COPD.11 However, data on responsiveness (response 
to interventions and ability to detect change) and minimal 
important difference (MID), which are necessary for the effec-
tive use of PPAC instruments as study outcomes, have not yet 
been reported. Moreover, reliability and validity of PPAC instru-
ments across different severity stages, countries and languages 
need to be reported in order to support their widespread use.
This study aimed to confirm the reliability and validity of 
the PPAC instruments in multiple independent patient samples, 
to test their responsiveness and to define their MIDs in a large 
population of patients with varying COPD severity from diverse 
settings and countries.
METHODS
A complete version of methods is available in an online supple-
mental file.
Study design and subjects
We retrospectively pooled data from seven prospective 
randomised controlled trials testing the effect of pharmaco-
logical and non- pharmacological interventions in patients with 
COPD from 17 countries in Europe and North America: the 
ACTIVATE (Effect of Aclidinium/Formoterol on Lung Hyperin-
flation, Exercise Capacity and Physical Activity in Moderate to 
Severe COPD Patients, NCT02424344),13 ATHENS (Pulmonary 
Rehabilitation Program and PROactive Tool, NCT02437994),14 
EXOS (Exercise Outcome Study: a comprehensive compar-
ison of the sensitivity of common exercise outcome measures 
for COPD, ISRCTN:64759523),15 MrPAPP (Impact of Tele-
coaching Program on Physical Activity in Patients With COPD, 
NCT02158065),16 PHYSACTO (Effect of Inhaled Medica-
tion Together With Exercise and Activity Training on Exercise 
Capacity and Daily Activities in Patients With Chronic Lung 
Disease With Obstruction of Airways, NCT02085161),17 
TRIGON- T9 (Efficacy and Safety of Glycopyrrolate Bromide 
of COPD Patients, NCT02189577)18 and URBAN TRAINING 
(Effectiveness of an Intervention of Urban Training in Patients 
With COPD: a Randomised Controlled Trial, NCT01897298)19 
studies. Online supplemental table S1 provides details on each 
trial’s purpose, inclusion and exclusion criteria, design and 
intervention. Trials contributed differently to the evaluation of 
different measurement properties depending on when D- PPAC 
Figure 1 Contribution of each trial to the assessment of measurement properties of Daily- PROactive and Clinical visit- PROactive Physical Activity 
(D- PPAC and C- PPAC) instruments. ACTIVATE, Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in 
Moderate to Severe patients with chronic obstructive pulmonary disease (COPD), NCT02424344; ATHENS, Pulmonary Rehabilitation Program and 
PROactive Tool, NCT02437994; EXOS, Exercise Outcome Study: a comprehensive comparison of the sensitivity of common exercise outcome measures 
for COPD, ISRCTN:64759523; MrPAPP, Impact of Telecoaching Program on Physical Activity in patients with COPD, NCT02158065; PHYSACTO, Effect 
of Inhaled Medication Together with Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients with Chronic Lung Disease 
With Obstruction of Airways, NCT02085161; TRIGON- T9, Efficacy and Safety of Glycopyrrolate Bromide of patients with COPD, NCT02189577; URBAN 
TRAINING, Effectiveness of an Intervention of Urban Training in patients with COPD: a randomised controlled trial, NCT01897298.
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and C- PPAC were measured (figure 1). Briefly, all studies contrib-
uted to reliability–internal consistency and validity analyses with 
their baseline data; TRIGON- T9 contributed to reliability- test–
retest analysis with baseline and 14 days data; ACTIVATE (bron-
chodilator intervention) contributed to responsiveness with 
baseline and 8 weeks of data; PHYSACTO (bronchodilator with 
behavioural physical activity intervention), MrPAPP (behavioural 
physical activity intervention) and ATHENS contributed to 
responsiveness with baseline and 12 weeks of data and URBAN 
TRAINING (behavioural physical activity intervention) contrib-
uted to the responsiveness analysis with baseline and 12 months 
of data. All trials recruited patients with stable COPD defined 
by spirometry (according to the American Thoracic Society and 
European Respiratory Society criteria)20 and invited all patients 
to answer one of the PPAC questionnaires (except in MrPAPP 
that answered both D- PPAC and C- PPAC) and record physical 
activity data by wearing activity monitors. All trials were regis-
tered and approved by appropriate institutional review boards. 
Written informed consent was obtained from all patients.
Measures
D- PPAC and C- PPAC instruments require both questionnaire 
and activity monitor data. Patients completed D- PPAC and/or 
C- PPAC questionnaires, which had been previously developed 
using appropriate qualitative and quantitative research methods 
and culturally sensitive translations12 and a rigorous item reduc-
tion process following current European Medicines Agency 
(EMA)21 and US FDA10 guidance, as described elsewhere.11 In 
brief, the D- PPAC questionnaire consists of 7- items with a daily 
recall and needs to be completed every evening for a week via 
an electronic- handled device. The C- PPAC questionnaire has 
12 items with a 1- week recall and is completed at the day of 
each study visit in an electronic- handled device, a web- based 
system or using paper and pen. Patients also wore one of the 
activity monitors validated to be part of the PPAC instruments 
(DynaPort MoveMonitor, McRoberts B.V., The Netherlands or 
Actigraph G3Tx, Actigraph, Pensacola, Florida, USA) during 
waking time in 1 week at each study visit. Data from individ-
uals were considered valid if they recorded more than 8 hour 
of wearing time on at least 3 days (not necessarily consecutive) 
within 1 week. We calculated D- PPAC and C- PPAC scores by 
combining questionnaire items with two variables from activity 
monitors (steps/day and vector magnitude units (VMU)/min). 
Both for D- PPAC and C- PPAC instruments, three scores are 
generated (amount of physical activity, difficulty with physical 
activity and total physical activity experience) ranging from 0 
to 100, where higher numbers indicate a better score. For the 
D- PPAC instrument, we obtained scores for each day and calcu-
lated a weekly mean of D- PPAC amount, difficulty and total 
scores. For the C- PPAC instrument, a weekly measure for each 
score was obtained. D- PPAC and C- PPAC items and scoring 
equivalences are reported in the online supplemental file.
We also obtained information about: time in moderate- to- 
vigorous physical activity per day (>3 metabolic equivalents, 
MVPA) from the activity monitor; lung function by spirometry 
after reversibility testing; exercise capacity by 6 min walking 
distance (6MWD); the modified Medical Research Council 
Dyspnoea scale (mMRC), the Chronic Respiratory Disease 
Questionnaire (CRQ), the Clinical COPD Questionnaire (CCQ) 
and/or the COPD Assessment Test (CAT) and demographics, 
smoking history and clinical data (medical and COPD histo-
ries) from patients and medical records. Patients participating 
in follow- up visits also rated the global change of their physical 
activity experience in amount, difficulty and overall since base-
line to follow- up on a 7- point Likert- type scale, ranging from 
‘much worse’ to ‘much better’ (see online supplemental file).
Statistical analysis
The sample size calculations and complete statistical analysis 
are available in the online supplemental file. The analysis sets 
and statistical analysis plan were defined a priori based on study 
objectives. We used different study samples for the different 
measurement properties (figure 1). All analyses were performed 
separately for D- PPAC and C- PPAC amount, difficulty and total 
scores.
Reliability was evaluated in terms of internal consistency by the 
Cronbach’s alpha and test–retest reproducibility, using intraclass 
correlation coefficients (ICC) and Bland- Altman plots. (Internal 
consistency of the total scores was not tested because total scores 
are calculated as the mean of amount and difficulty scores and 
not from a list of items). Convergent validity was explored by 
testing the Spearman correlations between D- PPAC and C- PPAC 
scores and related constructs. A matrix of expected correlations 
for each variable was built a priori (online supplemental table 
S2 and Methods (complete version) in online supplemental file). 
We also tested known- group validity using one- way ANOVA 
test and pairwise comparisons of means adjusting for multiple 
comparisons using Bonferroni correction between groups a 
priori expected to have differences in physical activity experi-
ence. Reliability and validity analyses were done in all patients 
and stratifying by sex, age groups, COPD severity, country and 
language.
To quantify responsiveness (response to interventions and 
ability to detect change), we calculated the change (8 weeks, 
12 weeks or 12 months minus baseline) and the standardised 
response mean (SRM) in (1) each intervention group, using 
each study separately (a priori expected significant differences 
(p<0.05) in the changes between groups and SRM>|0.5| in 
difficulty and total scores after bronchodilator and pulmonary 
rehabilitation interventions, and in amount and total scores after 
behavioural physical activity interventions, see online supple-
mental table S3), (2) groups defined by the self- reported change 
in physical activity experience, using a pooled dataset (a priori 
expected significant differences (p<0.05) and SRM>|0.5| in 
PPAC scores between much worse/worse/slightly worse versus no 
change/slightly better and better/much better versus no change/
slightly better, see online supplemental table S3) and (3) groups 
defined according to having had COPD exacerbations during 
follow- up, using a pooled dataset (a priori expected significant 
differences (p<0.05) and SRM>|0.5| in PPAC scores between 
those having any COPD exacerbation during follow- up versus 
none). We established the MID by triangulation using an anchor- 
based approach22 and calculated distribution- based estimates 
to provide insight into minimal detectable change (MDC) (not 
formally established because of scarcity of data for C- PPAC). 
Analyses were performed using complete cases in STATA V.14 
(StataCorp, College Station, Texas, USA).
RESULTS
Distribution of D-PPAC and C-PPAC scores
From a total of 1595 patients with stable COPD participating 
in the original trials, 1324 (83%) had available data on activity 
monitor and D- PPAC and/or C- PPAC questionnaires. Among 
them, 950 and 651 patients were included in the D- PPAC and 
C- PPAC- related analyses, respectively. Baseline characteristics 
are shown in table 1 (overall) and S4 (stratified by study; of 
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note, differences between samples reflect intentional differences 
in inclusion/exclusion criteria between studies). Both D- PPAC 
and C- PPAC samples covered a wide range of COPD severity 
and objective physical activity levels and included patients from 
17 countries completing the PPAC instruments in 11 languages 
(online supplemental table S5). D- PPAC and C- PPAC amount 
scores covered the full range between 0 and 100 and were more 
heterogeneous than difficulty scores (figure 2). There were no 
patients reporting difficulty scores between 0 and 25 (ie, high 
difficulty). We observed small significant differences by gender 
and age group in the amount and total D- PPAC scores but not in 
any of C- PPAC scores. There was a trend towards lower values 
of all scores by airflow severity group.
Reliability and validity
D- PPAC and C- PPAC scores showed strong internal consistency 
in all subjects (online supplemental table S6) and after strati-
fication (figure 3). D- PPAC scores were reproducible over the 
2- week period with ICCs>0.8 (online supplemental table S7). 
Bland- Altman plots showed no relevant differences between 
weeks 1 and 2 D- PPAC scores in stable patients (mean difference 
of 0 for amount, 1.2 for difficulty and 0.6 for total on the 100- 
point scores). Agreement laid within predefined limits and there 
was no pattern in differences over the range of values (online 
supplemental figure S1).
Both overall and after stratification, D- PPAC and C- PPAC 
amount scores exhibited weak correlations with health- related 
quality of life (HRQoL) measures, moderate correlations with 
exercise capacity and strong correlations with objective phys-
ical activity levels. Difficulty scores showed moderate- to- strong 
correlations with dyspnoea, HRQoL and exercise capacity and 
low correlations with objective physical activity level except for 
one country (The Netherlands) (table 2, figure 4). All D- PPAC 
and C- PPAC scores differentiated statistically across moderate- 
to- very severe COPD severity stages, dyspnoea grades (0–4) 
and tertiles of 6MWD, suggesting good known- group validity 
(online supplemental table S8).
Responsiveness and MID
Large SRM values and significant between- arm differences were 
found for (follow- up—baseline) changes in D- PPAC difficulty 
scores after the PHYSACTO and ACTIVATE (bronchodilators) 
interventions and for changes in the D- PPAC amount score after 
MrPAPP (behavioural physical activity) intervention (table 3). 
Changes in C- PPAC difficulty score were significantly different 
after the ATHENS (pulmonary rehabilitation) intervention, 
as were changes in C- PPAC amount score after MrPAPP and 
URBAN TRAINING (behavioural physical activity) interven-
tions. All scores were responsive to the self- reported rating of 
changes in physical activity experience (both worsening and 
improvement) and to the presence of COPD exacerbations 
during follow- up.
From anchor- based estimates (online supplemental tables S4 
and S9), we suggest a MID of 6 for the D- PPAC and C- PPAC 
amount and difficulty scores and 4 for the total scores. Distribu-
tion estimates for MDC produced very similar values.
DISCUSSION
By pooling data from a diverse population of patients with 
COPD from seven randomised controlled trials, we are the first 
to report the performance of the D- PPAC and C- PPAC instru-
mentsin COPD. Key findings are that D- PPAC and C- PPAC 
amount, difficulty and total scores (1) exhibit wide variation 
appropriate to patients with differing clinical characteristics, 
(2) show good internal consistency and construct validity across 
sex, age group, COPD severity, countries and languages, (3) are 
responsive to interventions and to changes in clinically relevant 
variables and (4) we established a MID of 6 for the amount and 
difficulty scores and of 4 for the total scores.
Table 1 Baseline demographic and clinical characteristics of 






n* m (SD)/n (%) n* m (SD)/n (%)
Age (years) 950 64.5 (7.7) 651 67.7 (8.5)
Gender: male 950 597 (63) 651 486 (75)
Working status: employed 352 48 (14) 643 79 (12)
Current smoker 950 394 (41) 651 157 (24)
BMI (kg/m2) 950 27.0 (5.1) 651 27.3 (5.1)
Any cardiovascular disease 721 178 (25) 593 255 (43)
Diabetes 950 91 (10) 593 112 (19)
Musculoskeletal disorders 720 193 (27) 599 95 (16)
FEV1 (% predicted) 949 54 (17) 651 56 (20)
ATS/ERS stages: 949 651
  I—mild (FEV1 ≥80%) 55 (6) 80 (12)
  II—moderate (FEV1 <80% and ≥50%) 489 (51) 308 (47)
  III—severe (FEV1 <50% and ≥30% 339 (36) 202 (31)
  IV—very severe (FEV1 <30%) 66 (7) 61 (10)
FVC (% predicted) 949 96 (21) 651 84 (21)
FEV1/FVC (%) 949 48 (12) 651 51 (14)
6MWD (m) 631 446 (102) 648 462 (105)
Dyspnoea (mMRC 0–4) 861 1.6 (0.9) 650 1.4 (1.0)
Any COPD exacerbations last 12 m 862 268 (31) 641 323 (51)
Any COPD exacerbations requiring 
admissions last 12 m
633 66 (10) 641 82 (13)
CRQ dyspnoea (1-7) 304 5.1 (1.4) 52 2.3 (0.7)
CRQ fatigue (1-7) 304 4.6 (1.2) 52 1.7 (0.5)
CRQ emotional (1-7) 304 5.2 (1.1) 52 3.4 (1.1)
CRQ mastery (1-7) 304 5.3 (1.3) 52 2.0 (0.6)
CCQ symptoms (0–6) 328 1.9 (1.1) 597 1.7 (1.1)
CCQ functional (0–6) 328 1.8 (1.3) 597 1.5 (1.2)
CCQ mental (0–6) 328 1.4 (1.4) 597 1.3 (1.4)
CCQ total (0–6) 328 1.8 (1.0) 649 1.6 (1.0)
CAT (0–40) 21 20 (6) 365 13 (7)
Steps per day (n/day) 950 5723 (3768) 651 6500 (4001)
VMU/min 950 428 (287) 651 442 (320)
Time in moderate- to- vigorous physical 
activity (min/day)
950 89 (51) 574 98 (48)
PPAC- amount (0–100) 950 54 (14) 651 70 (16)
PPAC- difficulty (0–100) 950 70 (14) 651 78 (15)
PPAC- total (0–100) 950 62 (10) 651 74 (12)
*Some variables have missing values and/or are only available in some studies. Online supplemental 
table S4 shows patients’ characteristics stratified by study.
ATS/ERS, American Thoracic Society and European Respiratory Society; BMI, body mass index; CAT, 
chronic obstructive pulmonary disease assessment test; CCQ, clinical chronic obstructive pulmonary 
disease questionnaire; COPD, chronic obstructive pulmonary disease; C- PPAC, Clinical visit version of 
PROactive Physical Activity in COPD instrument; CRQ, chronic respiratory questionnaire; D- PPAC, Daily 
version of PROactive Physical Activity in COPD instrument; FEV1, forced expiratory volume in 1 s; FVC, 
forced vital capacity; IC, inspiratory capacity; mMRC, modified medical research council dyspnoea scale; 
6MWD, 6 min walking distance; PPAC, PROactive physical activity in COPD; VMU, vector magnitude 
unit.
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This study provides important information for the future 
use of PPAC instruments. First, we found a wide distribution 
of D- PPAC and C- PPAC amount, difficulty and total scores, as 
expected by the fact that patients included in the seven clinical 
trials were quite diverse in terms of disease severity and recruit-
ment settings. Such variability in the scores supports the use of 
PPAC instruments to capture diversity in physical activity amount 
and difficulty as experienced by patients with COPD. Second, 
patients scored generally higher, that is, better, in the difficulty 
than in the amount domain. Qualitative and quantitative data 
from the development and initial validation studies of PPAC 
instruments,11 20 and current knowledge on physical activity 
and COPD,23 support that amount and difficulty are indeed 
two different dimensions of physical activity experience. Third, 
the amount domain covered virtually all potential values from 
0 to 100, which favours the notion that combining few ques-
tionnaire items with two activity monitor variables allows better 
capture of a wide spectrum of the patient- centred construct 
‘amount of physical activity’ than with an activity monitor 
alone, as previously shown.11 Fourth, the lack of patients scoring 
less than 25 in the difficulty domain (ie, reporting most diffi-
culty) could be due to underreporting or to the fact that none 
of the trials included exacerbating or extremely severe COPD 
patients. Further studies should test the PPAC instruments in 
these subpopulations. Finally, C- PPAC scores were higher than 
D- PPAC scores in all domains, with differences of >10 points in 
the amount domain (see MrPAPP D- PPAC and C- PPAC scores 
in online supplemental table S4). This could be attributed to 
recall bias in the weekly report towards higher amount of phys-
ical activity or to different cut- offs used for steps and VMU/
min between D- PPAC and C- PPAC versions (although the latter 
could not mathematically explain a>10 point difference). In any 
case, these results suggest that D- PPAC and C- PPAC instruments 
should not be used interchangeably in the same patient or study.
All scores of D- PPAC and C- PPAC instruments demonstrated 
good internal consistency and construct validity across sexes, 
age groups, COPD severities, countries and languages and very 
similar to those presented in the original development and vali-
dation study.11 One exception was the moderate correlation 
(higher than expected) between D- PPAC difficulty and MVPA in 
the Netherlands, including only 34 patients, that we consider a 
Figure 2 Distribution of D- PPAC and C- PPAC amount, difficulty and total scores, overall and stratified by gender, age group (quartiles) and 
COPD airflow severity groups. *p<0.05. Box indicates the lower and upper quartiles, the line subdividing the box represents the median, and lines 
(whiskers) represent 1.5 IQR of the nearer quartile (lower/upper adjacent values). C- PPAC, Clinical visit version of PROactive Physical Activity in COPD 
instrument; COPD, chronic obstructive pulmonary disease; D- PPAC, Daily version of PROactive Physical Activity in COPD instrument.
Figure 3 Cronbach’s alpha of D- PPAC and C- PPAC amount and 
difficulty scores, overall and stratified by gender, age group (quartiles) 
and COPD airflow severity groups (reliability, internal consistency). 
C- PPAC, Clinical visit version of PROactive Physical Activity in COPD 
instrument; COPD, chronic obstructive pulmonary disease; D- PPAC, Daily 
version of PROactive Physical Activity in COPD instrument.
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chance finding given that the rest of correlations in the Nether-
lands as well as all correlations for patients in Belgium (sharing 
the same language and geographic/climatic conditions as the 
Dutch) were within the range of other countries. Remarkably, 
observed correlations between PPAC scores and dyspnoea, 
HRQoL, exercise capacity and objective physical activity were 
very close to the a priori hypothesised, supporting that the PPAC 
instruments measure what they are meant to measure.
Table 2 Spearman correlation coefficients* of D- PPAC and C- PPAC scores with dyspnoea, health- related quality of life, exercise capacity and 
objective physical activity level (convergent validity)
D- PPAC C- PPAC
Amount Difficulty Total Amount Difficulty Total
Correlation P value Correlation P value Correlation P value Correlation P value Correlation P value Correlation P value
mMRC −0.20 <0.001 −0.40 <0.001 −0.40 <0.001 −0.40 <0.001 −0.64 <0.001 −0.65 <0.001
CRQ dyspnoea 0.16 0.006 0.68 <0.001 0.59 <0.001 0.28 0.045 0.61 <0.001 0.56 <0.001
CRQ fatigue 0.15 0.011 0.61 <0.001 0.52 <0.001 0.28 0.045 0.55 <0.001 0.51 <0.001
CRQ emotional 0.05 0.393 0.54 <0.001 0.41 <0.001 −0.20 0.028 −0.13 0.027 −0.18 0.008
CRQ mastery 0.08 0.143 0.53 <0.001 0.42 <0.001 0.00 0.989 0.64 <0.001 0.39 0.005
CCQ symptoms −0.20 <0.001 −0.56 <0.001 −0.50 <0.001 −0.18 <0.001 −0.55 <0.001 −0.45 <0.001
CCQ functional −0.36 <0.001 −0.77 <0.001 −0.74 <0.001 −0.34 <0.001 −0.76 <0.001 −0.69 <0.001
CCQ mental −0.28 <0.001 −0.55 <0.001 −0.52 <0.001 −0.19 <0.001 −0.50 <0.001 −0.42 <0.001
CCQ total −0.33 <0.001 −0.75 <0.001 −0.70 <0.001 −0.31 <0.001 −0.75 <0.001 −0.65 <0.001
CAT total n.a. n.a. n.a. −0.24 <0.001 −0.62 <0.001 −0.54 <0.001
6MWD 0.41 <0.001 0.40 <0.001 0.53 <0.001 0.49 <0.001 0.46 <0.001 0.53 <0.001
MVPA 0.67 <0.001 0.12 <0.001 0.53 <0.001 0.80 <0.001 0.30 <0.001 0.67 <0.001
*Correlation coefficients are in bold font when they met our assumptions (see online supplemental table S2 in the online data supplement) and normal font when they are higher or lower than expected.
CAT, chronic obstructive pulmonary disease assessment test; CCQ, clinical chronic obstructive pulmonary disease questionnaire; C- PPAC, Clinical visit version of PROactive Physical Activity in COPD instrument; CRQ, 
chronic respiratory questionnaire; D- PPAC, Daily version of PROactive Physical Activity in COPD instrument; mMRC, modified medical research council dyspnoea scale; MVPA, moderate- to- vigorous physical activity; 
6MWD, 6 min walk distance; n.a, Not available.
Figure 4 Correlation of D- PPAC and C- PPAC scores with CCQ- total, 6MWD and MVPA (convergent validity), overall and stratified by gender, age 
group (quartiles), COPD airflow severity groups, country and language. CCQ,Clinical COPD Questionnaire; C- PPAC, Clinical visit versionof PROactive 
Physical Activity in COPD instrument; COPD, chronic obstructive pulmonary disease; D- PPAC, Daily version of PROactive Physical Activity in COPD 
instrument, MVPA,moderate- to- vigorous physical activity; 6MWD,6 minwalking distance.
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Chronic obstructive pulmonary disease
In studies using pharmacological interventions, signifi-
cant differences were observed in the D- PPAC difficulty score 
after treatment with bronchodilators (ACTIVATE and PHYS-
ACTO).12 16 In non- pharmacological intervention studies, both 
D- PPAC and C- PPAC amount scores significantly improved after 
12 weeks of telecoaching (MrPAPP),15 a signal also observed in 
the ‘control’ group of PHYSACTO, which also received a self- 
management behavioural intervention that included coaching 
towards physical activity. As expected, C- PPAC difficulty score 
significantly improved after 12 weeks of an outpatient pulmo-
nary rehabilitation programme (ATHENS).13 Finally, the C- PPAC 
total score was able to detect even after 12 months a significant 
improvement following a behavioural and community- based 
exercise intervention (URBAN TRAINING).18 It is of note that 
prior to the trials included in this study, no interventions were 
available with a known effect on patients’ experience of phys-
ical activity. Our analyses support positive effects of broncho-
dilator therapy, pulmonary rehabilitation and physical activity 
behavioural interventions on these domains, which is relevant 
to COPD management. Finally, PPAC scores were able to detect 
changes (improvement or worsening) in self- reported physical 
activity experience and to decrease (worsen) significantly in 
patients who had experienced exacerbations during follow- up (8 
weeks, 12 weeks or 12 months, depending on the study). Alto-
gether makes these tools useful to serve as endpoints in clinical 
trials.
We suggest a MID of 6 for the amount and difficulty scores and 
of 4 for the total score, in scales ranging from 0 to 100. These 
values can identify differences in clinically relevant concepts such 
as HRQoL and patient self- report of physical activity change. 
Importantly, distribution- based estimates approximating the 
MDC gave very similar values (table 4), suggesting that changes 
that are important to patients can be detected by the PPAC instru-
ments. Given the prognostic value of objective physical activity,2 
as traditionally measured by an activity monitor, further studies 
should assess whether the defined MIDs for physical activity 
experience relate to morbidity and mortality of COPD.
The main limitation of our study is the lack of inclusion of 
exacerbating or recently exacerbated patients, which neither 
allow us to test the validity of the PPAC instruments in patients 
experiencing the most difficulty with physical activity nor to test 
the responsiveness of PPAC scores to interventions during exac-
erbations. Also, the PPAC instruments were tested in participants 
of clinical trials, who do not always reflect the general population 
of patients with COPD. However, some of the included trials 
recruited patients from primary care or with severe comorbidi-
ties. Finally, the heterogeneity in interventions and recruitment 
periods did not allow us to analyse if responsiveness differed by 
season, as previously shown in pulmonary rehabilitation.24
By using a number of different studies, conducted in different 
patient populations, the main strength of this study is that it 
covered a wider range of COPD disease severities, ages, objec-
tive physical activity levels and clinical determinants than what 
is usually seen in other questionnaire/patient- reported outcome 
development programmes. Moreover, patients from different 
countries and language groups were enrolled, supporting the 
use of the PPAC instruments in millions of patients with COPD 
in Europe and the North America. Also, responsiveness was 
tested against different types of interventions, which allowed 
understanding of how different domains of physical activity 
experience vary in response to different types of interventions, 
as discussed above. The diverse follow- up periods, that reflect 
expectations about when changes will occur after each inter-
vention, show that PPAC scores are able to identify changes in 
physical activity experience occurring at different time spans. 
Finally, although the study pooled data from independent drug 
and non- drug clinical trials with their own research objectives, 
the analysis was based on a priori defined hypothesis for all vali-
dation parameters.
Based on the previous11 and above evidence supporting the 
content validity, psychometric properties and usability of the 
PPAC instruments, the EMA in its final qualification opinion 
agrees that both instruments are suitable to capture physical 
activity experience in COPD patients and can thus be used as 
endpoints in clinical trials.25 Our results further support their 
use in future clinical trials and observational research studies. 
The fact that more than 1300 patients with COPD (83% of those 
participating in the original trials) completed the PPAC question-
naires and wore an activity monitor for at least 3 days in a week, 
which confirms acceptability and feasibility in a range of coun-
tries, languages and clinical scenarios. The use of the D- PPAC or 
C- PPAC version should depend on study objectives and try to 
balance patients’ burden. The D- PPAC questionnaire is shorter 
(seven questions) and less prone to recall bias, but requires daily 
report and availability of electronic- handled devices to fill in the 
questionnaire. Thus, the D- PPAC instrument is more likely to 
Table 4 Anchor- based estimates of the MID and distribution- based estimates of the MDC for D- PPAC and C- PPAC amount, difficulty and total 
scores
D- PPAC C- PPAC
Amount Difficulty Total Amount Difficulty Total
Anchor based
Change in CCQ total* 5.7 2.5 5.5 3.3
Change in amount of physical activity† 6.2 5.2 4.8 3.7
Change in difficulty with physical activity† 5.4 6.0 5.7 5.9 5.0
Change in physical activity experience overall† 4.8 4.8 5.8 4.1
Distribution based
0.5 of Cohen’s effect size 6.7 7.2 5.3 7.6 7.2 6.0
1 SEM (of ICC) 5.4 5.4 3.8
*Mean difference (final–baseline) in scores in patients who changed ≤−0.4 points in CCQ score.
†Mean difference (final–baseline) in scores in patients who rated their physical activity change as ‘better’ in amount, difficulty or overall.
CCQ, clinical COPD questionnaire; COPD, chronic obstructive pulmonary disease; C- PPAC, Clinical visit version of PROactive Physical Activity in COPD instrument; D- PPAC, Daily 
version of PROactive Physical Activity in COPD instrument; ICC, intraclass correlation coefficient ; MDC, minimal detectable change; MID, minimal important difference; SEM, 
standard error of measurement.
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be used where daily variations in physical activity experience or 
other outcomes or covariates are expected or in regulatory clin-
ical trials (by industry members) where physical activity experi-
ence is a primary outcome to obtain a label claim. The C- PPAC 
questionnaire (12 questions) is answered only once in a week and 
can also be completed in a website or in paper and pen, which 
increases feasibility but is subjected to some degrees of recall 
bias. Therefore, the C- PPAC instrument is more likely to be used 
where physical activity experience stability can be expected in 
a 1- week window, where patient burden of completing ques-
tionnaires is high or in pragmatic studies to gather ‘real- world’ 
evidence. A ‘PPAC User’s Guide’ is available from the authors 
describing the instruments, their administration procedures, 
scoring and translations available.
In conclusion, the D- PPAC and C- PPAC instruments are valid 
and reliable across sexes, age groups, COPD severities, countries 
and languages and are responsive to drug and non- drug treat-
ments and changes in clinically relevant variables.
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